Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Expert’s voice: GST 2.0 impact on IPO market and individuals

Promising updates for individuals, businesses, and investors: tired of facing rising tax burdens?? From 22nd September 2025, GST 2.0 would be utilised on all essential consumption products.
IPO Watch

What is GST 2.0?Ā 

GST 2.0 is the new version of India’s Goods and Services Tax system, launched in September 2025 to make taxes easier and cheaper for people and businesses. 

Additionally, it replaces the old four tax rates (5%, 12%, 18%, 28%) with just two: 5% and 18%.

However, there is also a high tax (40%) on sin and luxury goods. For a long time, businesses have also been waiting to remove the compensation cess, and now it is. 

22nd September is worth it for families, with every necessary item, appliance, and vehicle costing less. For businesses, tax paying will be easier, resulting in having more cash on hand. Investors can also take advantage of this; the upcoming IPO of good industries will provide an opportunity to grow faster and make a profit.Ā 

What central government and experts expect from GST 2.0?Ā 

  • The central government aims to raise around ₹48,000 crores through the tax reform.Ā 
  • Experts think these tax changes could slightly reduce inflation (by 0.20% to 0.30%), especially because food, everyday goods, and housing materials will become cheaper. This drop in prices could give the RBI more room to adjust interest rates if needed.Ā 

What states are worrying about?Ā 

Owing to GST 2.0, some states have concerns regarding a potential loss of between ₹80,000 crores and ₹1.5 lakh crores. 

How will business be boosted?Ā 

Besides cutting tax rates, the Council will also give faster refunds, make registration automatic, and fix tax problems, all to help companies work more smoothly. 

Positive announcement from a substantial voice:

As per the sources, there are major positive voices regarding GST 2.0 are given below. 

Axis Securities: People’s spending and economic growth could be due to GST 2.0. 

SBI Card CEO, Salila Pande: Enough money for spending, future planning, and saving. 

Confederation of Indian Industry (CII): Using just two tax rate systems instead of many is fruitful for investment and reduces problems. 

Commerce Minister Piyush Goyal said GST 2.0 supports the bigger goal of ā€˜Viksit Bharat 2047’ and helps build a stronger nation. 

All these essential voices are not just for small tax changes, but a sign of economic growth. 

As per the sources, Kotak AMC MD Nilesh Shah said that GST 2.0 is like ā€œone arrow hitting many targets.ā€ It helps increase spending and economic growth, and also helps reduce some of the problems caused by U.S. tariffs. 

Studies by SBI Research and Elara Capital say that GST 2.0 could boost GDP by 100–120 basis points (1%–1.2%) in 1 to 1.5 years. This may help balance out the slowdown caused by U.S. tariffs.

In the sharp contrast;Ā 

Marcellus CEO Saurabh Mukherjea warned that GST benefits will help, but industries like textiles, gems & jewellery, and sports goods are still at risk due to falling export demand.

Exporters like Nikkhil Masurkar (Entod Pharma) and Madan Sabnavis (Bank of Baroda) said GST relief can’t fully make up for losing export competitiveness, but it can help by boosting local demand for extra goods.

Which IPO sectors are impacted by GST 2.0?Ā 

Since last year, approximately 70 companies have received the green light from SEBI for IPO, and this GST 2.0 could be considered appropriate for them.Ā Ā 

Sector Company name GST 2.0 Impact Sentiment
Auto componentsMetalman Auto18% Positive
Greaves Electric MobilityEvs5% GSTPositive
Studds AccessoriesHelmets/gearHelp for affordable vehicles is increasing.Positive
Paras Healthcare, Veeda Clinical ResearchHealthcare & hospitalsCheaper medicine/ reduced GSTPositive
LG Electronics India, Kent RO Systems, Imagine Marketing (boAt)ElectronicsCut to 18% GSTPositive
Casagrand Premier Builder, Varindera Constructions, Runwal Enterprises, Pranav ConstructionsReal estate & infraCement GST cut (28%→18%) reduces costs/creates housing demandsPositive
Hero FinCorp, Aye Finance, Avanse Financial, Veritas FinanceFinancial servicesHigher savings/ buy insurance Positive
PMEA Solar Tech, Solarworld Energy, Continuum Green Energy, Juniper Green Energy, Saatvik Green Energy, GK EnergyRenewablesGST 5%Positive
GSP Crop Science, SeedWorks International, Advance AgrolifeAgri & inputsGST reduced/ strong demandpositive
WeWork India, Physicswallah, Jaro Institute, Urban CompanyServices/EdTechGST same: 18%/ Neutral to weak
Tobacco-related peers (if any)Sin goodsMoved into the 40% bracketNegative

GST 2.0 on Automobiles

Tax has been reduced from 28-30% to 18% on small cars and two-wheelers, and the luxury vehicles tax is 40% instead of 43% to 50%, still high. Especially, electronics vehicles have 5% tax; this tax reform allows people to spend more and buy their desire things. 

GST 2.0 on Consumer durablesĀ 

An essential product like TVs, air-conditioners, refrigerators, and washing machines, tax cut to 18%, allows individuals to save. 

FMCG & Packaged FoodsĀ 

Personal products like Shampoos, soaps, hair oil, and toothpaste now have a lower tax of 5% instead of 12–18%. Moreover, biscuits, noodles, chocolates, and coffee have 5% tax. 

Healthcare & InsuranceĀ 

Medicines and medical devices now have a tax of 5% or zero, making treatment cheaper. Industry leaders say this is a big step toward making healthcare affordable.

Real Estate & CementĀ 

Tax rate is cut from 28% to 18%, lowering housing project costs and helping builders earn 3–5% more. Sunteck Realty says this will boost affordable housing demand. 

Renewables

Solar panels, batteries, hydrogen fuel cells, and biogas units now have a 5% GST. Hindustan Power called this a big boost for green energy.

Coal’s tax went up from 5% to 18%, but because of changes in other taxes, the overall effect is small.

Fertiliser chemicals like sulphuric acid and ammonia now have a 5% tax instead of 18%.

Agricultural machines are also taxed at 5%, helping farmers use more machines and reduce costs.

Risk & Challenges

  • There might be temporary problems due to the old tax credit, and businesses need to have time to follow the new rules.Ā 
  • FMCG and appliance companies might keep some of the tax savings instead of passing them all to customers, so prices may not drop much.
  • Foreign investment in India also depends on things like U.S. interest rates, the strength of the dollar, and oil prices, not just India’s tax changes.
  • Businesses like gaming and sin goods (like alcohol or tobacco) have high taxes, which can hurt their market value.
  • Education, detergents, and online services still have the same 18% tax, so they have fewer benefits.

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi